Clinical Trial Update: A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial examining mRNA-1345 given after a licensed protein subunit RSV vaccine in adults aged 60 and older; study status is Active Not Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Licensed protein subunit RSV vaccine (primary dose) (RSV F protein subunit vaccine)
• mRNA-1345

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Respiratory Syncytial Virus | Phase 3 | Status: ACTIVE_NOT_RECRUITING